Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 09 Dec 2021 17:49 CET |
VACCIBODY | Registration of new share capital | 20103010 Biotechnology | Total number of voting rights and capital |
| 03 Dec 2021 17:26 CET |
VACCIBODY | Mandatory notification of trade by primary insiders and related parties | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 03 Dec 2021 16:49 CET |
VACCIBODY | Subscription of warrants | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 30 Nov 2021 13:30 CET |
VACCIBODY | Minutes of Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 24 Nov 2021 16:35 CET |
VACCIBODY | Nykode Therapeutics (formerly Vaccibody*)) resolves to issue shares to Regeneron | 20103010 Biotechnology | Total number of voting rights and capital |
| 23 Nov 2021 06:47 CET |
VACCIBODY | Nykode Therapeutics (formerly Vaccibody*)) enters into multi-target license and collaboration agreement with Regeneron to develop innovative vaccines against cancer and infectious diseases | 20103010 Biotechnology | Non-regulatory press releases |
| 23 Nov 2021 06:46 CET |
VACCIBODY | Vaccibody AS – Notice of Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Nov 2021 06:45 CET |
VACCIBODY | Vaccibody becomes Nykode Therapeutics - a new name and identity to signify a new phase of growth and development | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |